Oxford, Square 1 Provide Trevena $35MM Term Loan
Trevena announced it entered into a senior secured term loan credit facility providing for up to $35 million of funding, of which $2 million was drawn at closing. Trevena has the option to draw the remaining funds in two equal tranches upon positive clinical data in the company’s ongoing TRV130 and TRV027 studies. Oxford Finance is serving as collateral agent and lender, and Square 1 Bank is serving as lender.
“This facility strengthens our cash position and provides us with meaningful financial flexibility over the next 18 months,” said Maxine Gowen, PhD, president and CEO of Trevena. “If we receive positive Phase 2 clinical data in our ongoing studies, we can choose to draw on this facility to help fund further clinical development of our product candidates. We are delighted to be working with Oxford Finance and Square 1, and recognize in their commitment to us a shared belief in the potential benefits of Trevena’s drug candidates.”
“Oxford is pleased to support Trevena with this new financing,” said Christopher A. Herr, managing director for Oxford Finance. “Through our diligence process we have developed strong confidence in the Trevena team and the Company’s pipeline of promising new therapies.”
In addition to the $2 million initial term loan tranche, the facility provides for up to two additional term loan tranches of $16.5 million each. Trevena may opt to draw the second term loan tranche upon the receipt of positive efficacy data from the phase 2 study of TRV130 and the third term loan tranche upon the receipt of positive data from the phase 2 study of TRV027. Trevena currently expects data from the phase 2 bunionectomy study of TRV130 at the latest by the first quarter of 2015, and from the phase 2 BLAST-AHF trial of TRV027 in acute heart failure by the end of 2015. The term loans bear interest at a rate of 6.5% per annum, and the maturity date for the credit facility is December 1, 2018. At the maturity date, a fee of between 5.25% and 7.0% of the amount borrowed will be due. In certain circumstances, the maturity date may be extended to September 1, 2019.
Trevena is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs.